采用气相色谱-质谱联用技术对血浆和尿液中的治疗用γ-羟基丁酸进行监测。

Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry.

作者信息

Ferrara S D, Tedeschi L, Frison G, Castagna F, Gallimberti L, Giorgetti R, Gessa G L, Palatini P

机构信息

Centre of Behavioural and Forensic Toxicology, University of Padova, Italy.

出版信息

J Pharm Biomed Anal. 1993 Jun;11(6):483-7. doi: 10.1016/0731-7085(93)80161-s.

DOI:10.1016/0731-7085(93)80161-s

PMID:8399519

Abstract

A gas chromatographic-mass spectrometric (GC-MS) method for the determination of therapeutic levels of gamma-hydroxybutyric acid (GHB) in plasma and urine samples is described. GHB is converted to its lactonic form gamma-butyrolactone (GBL) which is extracted from biological fluids after the addition of the internal standard delta-valerolactone. Final GC-MS analysis is obtained under electron impact selected ion monitoring (SIM) conditions. Mean relative recoveries of GHB from plasma and urine are 75.5% (RSD% = 2.2) and 76.4% (RSD% = 2.4), respectively. The assay is linear over a plasma GHB range of 2-200 micrograms ml-1 (r = 0.999) and a urine GHB range of 2-150 micrograms ml-1 (r = 0.998). Intra- and inter-assay relative standard deviations (n = 5) determined at 10 and 100 micrograms ml-1 are below 5%. The method is simple, specific and accurate, and may be applied for analytical purposes related to pharmacokinetic studies and therapeutic drug monitoring.

摘要

本文描述了一种用于测定血浆和尿液样本中γ-羟基丁酸（GHB）治疗水平的气相色谱-质谱联用（GC-MS）方法。GHB被转化为其内酯形式γ-丁内酯（GBL），在加入内标δ-戊内酯后从生物流体中提取。最终的GC-MS分析在电子轰击选择离子监测（SIM）条件下进行。GHB在血浆和尿液中的平均相对回收率分别为75.5%（相对标准偏差% = 2.2）和76.4%（相对标准偏差% = 2.4）。该测定法在血浆GHB浓度范围为2 - 200微克/毫升（r = 0.999）和尿液GHB浓度范围为2 - 150微克/毫升（r = 0.998）内呈线性。在10和100微克/毫升处测定的批内和批间相对标准偏差（n = 5）低于5%。该方法简单、特异且准确，可用于与药代动力学研究和治疗药物监测相关的分析目的。